Teneligliptin with Metformin
Teneligliptin with Metformin is a combination medication used to treat Type 2 Diabetes Mellitus. It consists of two active ingredients: Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin, a biguanide.This combination is indicated for the management of Type 2 Diabetes Mellitus in adults when diet and exercise alone do not provide adequate glycemic control.
Dosage should be individualized based on the patient's response and tolerability. Typical starting dose: One tablet daily, with or after meals. The dosage may be adjusted as per the physician's recommendation.
-Hypersensitivity to Teneligliptin or Metformin. -Severe renal impairment or end-stage renal disease. -Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
-Renal function should be assessed before initiating treatment and periodically thereafter. -Discontinue if lactic acidosis or pancreatitis is suspected. -Caution in patients at risk for heart failure or with a history of angioedema.
Common side effects may include gastrointestinal symptoms (nausea, vomiting, diarrhea), hypoglycemia, nasopharyngitis, and headache. Rare but serious side effects include lactic acidosis and pancreatitis.
-Cationic drugs that are eliminated by renal tubular secretion may interact with Metformin. -Avoid concurrent use with other DPP-4 inhibitors or medications that increase the risk of lactic acidosis.
